Pharmacokinetics and safety of TCMCB07, a melanocortin‐4 antagonist peptide in dogs

The melanocortin‐4 receptor (MC4R) antagonistic peptide TCMCB07 was developed for the treatment of cachexia. The objectives of this study were to examine pharmacokinetics and safety of TCMCB07 administered subcutaneously to healthy dogs. Dogs were treated with high‐ (2.25 mg kg(−1)) (n = 5) and low‐...

Descripción completa

Detalles Bibliográficos
Autores principales: Axiak‐Bechtel, Sandra M., Leach, Stacey B., Scholten, David G., Newton‐Northup, Jessica R., Johnson, Brendan J., Durham, H. E., Gruber, Kenneth A., Callahan, Michael F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8135083/
https://www.ncbi.nlm.nih.gov/pubmed/34014033
http://dx.doi.org/10.1002/prp2.777

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8135083/
https://www.ncbi.nlm.nih.gov/pubmed/34014033
http://dx.doi.org/10.1002/prp2.777

Ejemplares similares